Tesamorelin + Ipamorelin Blend
Quick summary
A blend that pairs a GHRH analog (tesamorelin) with a ghrelin-receptor agonist (ipamorelin), which act on two separate receptor pathways for growth-hormone release. Research focus: GH secretagogue synergy and pituitary signaling. This page leads with SRP's low-and-slow starting dose.
Component structures:
Amino acid sequence (one-letter code): AHFFK
Overview
A blend that pairs a GHRH analog (tesamorelin) with a ghrelin-receptor agonist (ipamorelin), which act on two separate receptor pathways for growth-hormone release.
Looking for research material? Simple Research Peptides lists Tesamorelin + Ipamorelin Blend 8mg for laboratory research use.
Mechanism
This blend combines its components, each acting through its own pathway. See the linked component pages for how each one works.
Research areas
- GH secretagogue synergy
- pituitary signaling
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Starting low and holding for one to two weeks before stepping up, but gives no numeric starting draw for the blend. Component reference amounts: tesamorelin 1-2 mg and ipamorelin 200-300 mcg. |
|---|---|
| Frequency | Once daily by subcutaneous injection, often in the evening; typical cycle 8-16 weeks. |
| Reconstitution | For the supplier's two blend ratios: add 3 mL bacteriostatic water to either vial - the 10/3 mg vial (10 mg tesamorelin + 3 mg ipamorelin) gives about 4.33 mg/mL total, and the 5/5 mg vial gives about 3.33 mg/mL total. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | No ceiling for the blend; component reference ranges only: tesamorelin 1-2 mg once daily and ipamorelin 200-300 mcg once or twice daily. No human trial has tested the two as a blend. |
|---|---|
| Step-up schedules reported | Gradual: start low, hold a week or two, then step up. No step schedule is given; sample draws shown are 10, 20 or 30 units. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; IGF-1, fasting glucose and HbA1c.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Tesamorelin + Ipamorelin Blend studied for?
In research it is studied for GH secretagogue synergy and pituitary signaling. This blend combines its components, each acting through its own pathway.
How is Tesamorelin + Ipamorelin Blend given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026